BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Falcone I, Conciatori F, Bazzichetto C, Bria E, Carbognin L, Malaguti P, Ferretti G, Cognetti F, Milella M, Ciuffreda L. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations. Int J Mol Sci 2020;21:E8419. [PMID: 33182542 DOI: 10.3390/ijms21228419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Chang H, An R, Li X, Lang X, Feng J, Lv M. Anti-Axl monoclonal antibodies attenuate the migration of MDA-MB-231 breast cancer cells. Oncol Lett 2021;22:749. [PMID: 34539853 DOI: 10.3892/ol.2021.13010] [Reference Citation Analysis]
2 Cai GX, Lin L, Zhai XM, Guo ZW, Wu YS, Ye GL, Liu Q, Chen LS, Xing GY, Zhao QH, Tang LL, Mai SH, Ye BJ. A plasma-derived extracellular vesicle mRNA classifier for the detection of breast cancer. Gland Surg 2021;10:2002-9. [PMID: 34268084 DOI: 10.21037/gs-21-275] [Reference Citation Analysis]
3 Xu T, Yu S, Zhang J, Wu S. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers. J Hematol Oncol 2021;14:181. [PMID: 34717710 DOI: 10.1186/s13045-021-01198-9] [Reference Citation Analysis]
4 Brosseron F, Maass A, Kleineidam L, Ravichandran KA, González PG, McManus RM, Ising C, Santarelli F, Kolbe CC, Häsler LM, Wolfsgruber S, Marquié M, Boada M, Orellana A, de Rojas I, Röske S, Peters O, Cosma NC, Cetindag A, Wang X, Priller J, Spruth EJ, Altenstein S, Schneider A, Fliessbach K, Wiltfang J, Schott BH, Bürger K, Janowitz D, Dichgans M, Perneczky R, Rauchmann BS, Teipel S, Kilimann I, Göerß D, Laske C, Munk MH, Düzel E, Yakupov R, Dobisch L, Metzger CD, Glanz W, Ewers M, Dechent P, Haynes JD, Scheffler K, Roy N, Rostamzadeh A, Teunissen CE, Marchant NL, Spottke A, Jucker M, Latz E, Wagner M, Mengel D, Synofzik M, Jessen F, Ramirez A, Ruiz A, Heneka MT; DELCODE study group. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. Neuron 2021:S0896-6273(21)01033-3. [PMID: 34995486 DOI: 10.1016/j.neuron.2021.12.016] [Reference Citation Analysis]
5 Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K. AXL inhibition improves BRAF-targeted treatment in melanoma. Sci Rep 2022;12:5076. [PMID: 35332208 DOI: 10.1038/s41598-022-09078-z] [Reference Citation Analysis]
6 Mongre RK, Mishra CB, Shukla AK, Prakash A, Jung S, Ashraf-Uz-Zaman M, Lee MS. Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure? Int J Mol Sci 2021;22:11659. [PMID: 34769090 DOI: 10.3390/ijms222111659] [Reference Citation Analysis]